Neubase Therapeutics Stock Net Asset
NBSEDelisted Stock | USD 1.62 0.17 9.50% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
NeuBase |
NeuBase Therapeutics Company Net Asset Analysis
NeuBase Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current NeuBase Therapeutics Net Asset | 32.69 M |
Most of NeuBase Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, NeuBase Therapeutics has a Net Asset of 32.69 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
NeuBase Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeuBase Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics of similar companies.NeuBase Therapeutics is currently under evaluation in net asset category among its peers.
NeuBase Fundamentals
Return On Equity | -0.93 | |||
Return On Asset | -0.43 | |||
Current Valuation | (5.83 M) | |||
Shares Outstanding | 3.75 M | |||
Shares Owned By Insiders | 13.37 % | |||
Shares Owned By Institutions | 12.68 % | |||
Number Of Shares Shorted | 15.57 K | |||
Price To Earning | (4.17) X | |||
Price To Book | 0.18 X | |||
EBITDA | (32.49 M) | |||
Net Income | (33.78 M) | |||
Cash And Equivalents | 29.85 M | |||
Cash Per Share | 0.93 X | |||
Total Debt | 6 M | |||
Debt To Equity | 0.20 % | |||
Current Ratio | 7.53 X | |||
Book Value Per Share | 2.45 X | |||
Cash Flow From Operations | (29.01 M) | |||
Short Ratio | 0.24 X | |||
Earnings Per Share | (18.60) X | |||
Price To Earnings To Growth | (0.07) X | |||
Target Price | 140.0 | |||
Number Of Employees | 37 | |||
Beta | 0.95 | |||
Market Capitalization | 1.42 M | |||
Total Asset | 32.69 M | |||
Retained Earnings | (102.74 M) | |||
Working Capital | 20.48 M | |||
Current Asset | 4.14 M | |||
Current Liabilities | 1.6 M | |||
Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |